DrugBiological
Ciltacabtagene autoleucel clinical trials
Also written JNJ-68284528.
Keep track of what changes. Save the ciltacabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Janssen Research & Development, LLC (5) · Dana-Farber Cancer Institute (1) · Janssen Scientific Affairs, LLC (1) · Washington University School of Medicine (1) · Medical College of Wisconsin (1) · Nanjing Legend Biotech Co. (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (2) · Pomalidomide (1) · Bortezomib (1) · Dexamethasone (1) · Daratumumab (1) · Fludarabine phosphate (1) · Fludarabine (1) · Talquetamab (1)
Studies
Open first, then newest update. How each study uses ciltacabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingPhase 4Janssen Research & Development, LLCNCT05201781Written as Cilta-cel
- Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionRecruitingPhase 1Washington University School of MedicineNCT06623630Written as Ciltacabtagene Autoleucel
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1Medical College of WisconsinNCT07093554Written as Ciltacabtagene Autoleucel
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04181827Written as Cilta-cel
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT04133636Written as JNJ-68284528
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04923893Written as Cilta-cel
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT05767359Written as Ciltacabtagene Autoleucel
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedPhase 2Nanjing Legend Biotech Co.NCT03758417Written as LCAR-B38M CAR-T Cell
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple MyelomaCompletedPhase 1/2Janssen Research & Development, LLCNCT03548207Written as JNJ-68284528
- A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedPhase 2Janssen Scientific Affairs, LLCNCT05347485Written as Cilta-cel
Given in every arm · 5 — ciltacabtagene autoleucel is usual care beside what is tested
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingPhase 2Janssen Research & Development, LLCNCT07149857Written as Cilta-cel
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 2Mayo ClinicNCT06940297Written as Ciltacabtagene Autoleucel
- A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06550895Written as Cilta-cel
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT06577025Written as Cilta-cel
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3Stichting European Myeloma NetworkNCT05257083Written as Cilta-cel
Codes
What other systems call ciltacabtagene autoleucel · ClinicalTrials.gg INT014205
- UNII (FDA) 0L1F17908QCILTACABTAGENE AUTOLEUCELOne source FDA
- RxNorm 2594775One source FDA
- NCI Thesaurus C148498Ciltacabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0L1F17908Q | CILTACABTAGENE AUTOLEUCEL | One source FDA |
| RxNorm | 2594775 | — | One source FDA |
| NCI Thesaurus | C148498 | Ciltacabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.